Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
Homerun Resources Inc. Announces Signing of Definitive Surface Rights Agreement for the Installation of Its Industrial Projects in Santa Maria Eterna, Belmonte, Bahia, Brazil
